Join
Live feed
·
PRReleasevia Quantisnow
INmune Bio Inc. logo

INmune Bio acquires LUMICKS' z-Movi® Cell Avidity Analyzer to accelerate the development of its NK cell platform for cancer treatments

ByQuantisnow·Wall Street's wire, on your screen.
INMB· INmune Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INMB (INmune Bio Inc.) and more on Quantisnow.